At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...

NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...

The increasing demand for biopharmaceuticals is a significant driver of the Global Bioanalytical Services market Industry US, NY, UNITED STATES, January 22, 2025 /EINPresswire / -- Global ...

China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...

In Ireland, WuXi Biologics has sold a new vaccine plant to Merck & Co. for €500 million ($521 million). The New Jersey company was a natural buyer of the facility as it was the lone client WuXi ...

Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company's cash flow and margins as it navigates global ...